EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis

Ting-Sha He, Rong-Hui Chen, Jing Feng, Qiang Zhang, Xin-Ling Li, Jia-Hui Han, Tian-Ze Chen, Rong-Min Yu iD, Li-Yan Song, Wei-Juan Huang

Cancer Medicine · 2026-04 · 15 (4)

DOI: 10.1002/cam4.71796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 14.04.2026. Verfasst von Ting-Sha He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Claudins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arteannuin B (Art B), a sesquiterpene lactone from Artemisia annua , combats non‐small cell lung cancer (NSCLC) chemoresistance by activating a novel miR‐194‐3p/CLDN2 axis, as identified here through integrated transcriptomic and functional analyses. Here, we combined transcriptomic profiling with functional validation to identify claudin‐2 (CLDN2) as a critical mediator of Art B's anticancer effects in NSCLC. CLDN2 , significantly upregulated in NSCLC tissues versus paired normal tissues, promoted tumor cell proliferation and cisplatin resistance by upregulating multidrug resistance‐associated protein 2 (MRP2). Mechanistically, miR‐194‐3p directly binds to two conserved sites (nt 358–365 and 1232–1238) within the CLDN2 3′ UTR, suppressing its expression via mRNA degradation and translational inhibition, thereby attenuating proliferation and resensitizing cells to cisplatin. Importantly, Art B exerted antitumor effects by upregulating miR‐194‐3p , which subsequently inhibited CLDN2 . This study not only elucidates a previously unrecognized mechanism for overcoming chemoresistance but also nominates CLDN2 as a prognostic biomarker, offering a promising therapeutic strategy that could benefit NSCLC patients facing treatment failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCarcinoma, Non-Small-Cell LungLung NeoplasmsClaudinsSesquiterpenesLactonesHumansGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmCell ProliferationCell Line, TumorCisplatinAnimals3' Untranslated RegionsMultidrug Resistance-Associated Protein 2ATP-Binding Cassette, Sub-Family C ProteinsMice

Stichwörter der Autor:innen

CLDN2Arteannuin BNSCLCchemoresistancemiR‐194‐3p

Substanzen

MicroRNAsCLDN2 protein, humanCisplatinClaudinsSesquiterpenes3' Untranslated RegionsMultidrug Resistance-Associated Protein 2LactonesATP-Binding Cassette, Sub-Family C Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
  • Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou, China.
  • Department of Chinese Materia Medica, College of Pharmacy, Jinan University, Guangzhou, China.

ORCID-Profile: Rong-Min Yu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

He, T. S., Chen, R. H., Feng, J., Zhang, Q., Li, X. L., Han, J. H., Chen, T. Z., Yu, R. M., Song, L. Y., & Huang, W. J. (2026). Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71796

Vancouver

He TS, Chen RH, Feng J, Zhang Q, Li XL, Han JH, et al. Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71796

BibTeX
@article{He2026,
  author = {He, Ting-Sha and Chen, Rong-Hui and Feng, Jing and Zhang, Qiang and Li, Xin-Ling and Han, Jia-Hui and Chen, Tian-Ze and Yu, Rong-Min and Song, Li-Yan and Huang, Wei-Juan},
  title = {Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cam4.71796}
}
Kostenlos starten →